{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:13:24Z","timestamp":1782159204655,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72274045"],"award-info":[{"award-number":["72274045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11136-026-04183-2","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:34:02Z","timestamp":1772958842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer-specific or generic preference-based measures in oncology? A validity comparison across six commonly diagnosed cancers"],"prefix":"10.1007","volume":"35","author":[{"given":"Yiyin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakhno","family":"Alina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"3","key":"4183_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"4","key":"4183_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen, S., Cao, Z., Prettner, K., Kuhn, M., Yang, J., Jiao, L., Wang, Z., Li, W., Geldsetzer, P., B\u00e4rnighausen, T., Bloom, D. E., & Wang, C. (2023). Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncology, 9(4), 465\u2013472. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826","journal-title":"JAMA Oncology"},{"issue":"2","key":"4183_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.healthpol.2018.11.003","volume":"123","author":"L Maynou","year":"2019","unstructured":"Maynou, L., & Cairns, J. (2019). What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Health Policy, 123(2), 130\u2013139. https:\/\/doi.org\/10.1016\/j.healthpol.2018.11.003","journal-title":"Health Policy"},{"issue":"5","key":"4183_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1586\/14737167.2013.837766","volume":"13","author":"A Bracco","year":"2013","unstructured":"Bracco, A., & Krol, M. (2013). Economic evaluations in European reimbursement submission guidelines: Current status and comparisons. Expert Review of Pharmacoeconomics & Outcomes Research, 13(5), 579\u2013595. https:\/\/doi.org\/10.1586\/14737167.2013.837766","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"3","key":"4183_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1017\/s0266462311000274","volume":"27","author":"J Mauskopf","year":"2011","unstructured":"Mauskopf, J., Walter, J., Birt, J., Bowman, L., Copley-Merriman, C., & Drummond, M. (2011). Differences among formulary submission guidelines: Implications for health technology assessment. International Journal of Technology Assessment in Health Care, 27(3), 261\u2013270. https:\/\/doi.org\/10.1017\/s0266462311000274","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"4183_CR6","unstructured":"National Institute for Health and Care Excellence. (2013). NICE process and methods guides. In Guide to the Methods of Technology Appraisal 2013. National Institute for Health and Care Excellence (NICE)."},{"key":"4183_CR7","unstructured":"Copyright \u00a9 2013 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved."},{"issue":"3","key":"4183_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40258-020-00634-0","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Qiu, T., Zhou, J., Francois, C., & Toumi, M. (2021). Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian countries. Applied Health Economics and Health Policy, 19(3), 281\u2013304. https:\/\/doi.org\/10.1007\/s40258-020-00634-0","journal-title":"Applied Health Economics and Health Policy"},{"issue":"6","key":"4183_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10198-022-01523-0","volume":"24","author":"CW Pan","year":"2023","unstructured":"Pan, C. W., He, J. Y., Zhu, Y. B., Zhao, C. H., Luo, N., & Wang, P. (2023). Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients. European Journal of Health Economics, 24(6), 885\u2013893. https:\/\/doi.org\/10.1007\/s10198-022-01523-0","journal-title":"European Journal of Health Economics"},{"issue":"1","key":"4183_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01867-w","volume":"19","author":"NB Bulamu","year":"2021","unstructured":"Bulamu, N. B., Vissapragada, R., Chen, G., Ratcliffe, J., Mudge, L. A., Smithers, B. M., Isenring, E. A., Smith, L., Jamieson, G. G., & Watson, D. I. (2021). Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy. Health and Quality of Life Outcomes, 19(1), Article 233. https:\/\/doi.org\/10.1186\/s12955-021-01867-w","journal-title":"Health and Quality of Life Outcomes"},{"key":"4183_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jclinepi.2021.03.015","volume":"137","author":"EM Gamper","year":"2021","unstructured":"Gamper, E. M., Cottone, F., Sommer, K., Norman, R., King, M., Breccia, M., Caocci, G., Patriarca, A., Palumbo, G. A., Stauder, R., Niscola, P., Platzbecker, U., Caers, J., Vignetti, M., & Efficace, F. (2021). The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 137, 31\u201344. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.015","journal-title":"Journal of Clinical Epidemiology"},{"key":"4183_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jclinepi.2022.09.010","volume":"152","author":"CP Klapproth","year":"2022","unstructured":"Klapproth, C. P., Fischer, F., Rose, M., & Karsten, M. M. (2022). Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS preference score. Journal of Clinical Epidemiology, 152, 101\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.09.010","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"4183_CR13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.jval.2021.05.022","volume":"24","author":"JW Shaw","year":"2021","unstructured":"Shaw, J. W., Bennett, B., Trigg, A., DeRosa, M., Taylor, F., Kiff, C., Ntais, D., Noon, K., King, M. T., & Cocks, K. (2021). A comparison of generic and condition-specific preference-based measures using data from Nivolumab trials: EQ-5D-3L, mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions. Value in Health, 24(11), 1651\u20131659. https:\/\/doi.org\/10.1016\/j.jval.2021.05.022","journal-title":"Value in Health"},{"issue":"1","key":"4183_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-0185-3","volume":"4","author":"M Herdman","year":"2020","unstructured":"Herdman, M., Kerr, C., Pavesi, M., Garside, J., Lloyd, A., Cubi-Molla, P., & Devlin, N. (2020). Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed\/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. Journal of Patient-Reported Outcomes, 4(1), Article 22. https:\/\/doi.org\/10.1186\/s41687-020-0185-3","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"4183_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0502-y","volume":"14","author":"S Kularatna","year":"2016","unstructured":"Kularatna, S., Whitty, J. A., Johnson, N. W., Jayasinghe, R., & Scuffham, P. A. (2016). A comparison of health state utility values associated with oral potentially malignant disorders and oral cancer in Sri Lanka assessed using the EQ-5D-3 L and the EORTC-8D. Health and Quality of Life Outcomes, 14, Article 101. https:\/\/doi.org\/10.1186\/s12955-016-0502-y","journal-title":"Health and Quality of Life Outcomes"},{"issue":"5","key":"4183_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14737167.2023.2189590","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A., Mao, Z., Wang, Z., Wu, J., Luo, N., & Wang, P. (2023). Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: A scoping review. Expert Review of Pharmacoeconomics & Outcomes Research, 23(5), 449\u2013468. https:\/\/doi.org\/10.1080\/14737167.2023.2189590","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"6","key":"4183_CR17","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1177\/0272989x11421529","volume":"31","author":"DG Whitehurst","year":"2011","unstructured":"Whitehurst, D. G., Bryan, S., & Lewis, M. (2011). Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores. Medical Decision Making, 31(6), E34-44. https:\/\/doi.org\/10.1177\/0272989x11421529","journal-title":"Medical Decision Making"},{"issue":"11","key":"4183_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-016-1375-6","volume":"25","author":"F Rencz","year":"2016","unstructured":"Rencz, F., Gul\u00e1csi, L., Drummond, M., Golicki, D., & P\u00e9ntek, M. (2016). EQ-5D in Central and Eastern Europe: 2000\u20132015. Quality of Life Research, 25(11), 1\u201318.","journal-title":"Quality of Life Research"},{"key":"4183_CR19","unstructured":"Chun-Lin, J., Hai-Yin, W., & Jie, C. (2014). Methods, applications and recommendations for health technology assessment. Chinese Health Resources."},{"key":"4183_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/11588250-000000000-00000","volume":"29","author":"M Garau","year":"2011","unstructured":"Garau, M., Shah, K. K., Mason, A. R., Wang, Q., Towse, A., & Drummond, M. F. (2011). Using QALYs in cancer: A review of the methodological limitations. PharmacoEconomics, 29, 673\u2013685.","journal-title":"PharmacoEconomics"},{"issue":"7","key":"4183_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717\u20131727. https:\/\/doi.org\/10.1007\/s11136-012-0322-4","journal-title":"Quality of Life Research"},{"issue":"11","key":"4183_CR22","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/s11136-020-02576-5","volume":"29","author":"G Chen","year":"2020","unstructured":"Chen, G., & Olsen, J. A. (2020). Filling the psycho-social gap in the EQ-5D: The empirical support for four bolt-on dimensions. Quality of Life Research, 29(11), 3119\u20133129. https:\/\/doi.org\/10.1007\/s11136-020-02576-5","journal-title":"Quality of Life Research"},{"issue":"2","key":"4183_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13696998.2016.1241788","volume":"20","author":"ER Marriott","year":"2017","unstructured":"Marriott, E. R., van Hazel, G., Gibbs, P., & Hatswell, A. J. (2017). Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Journal of Medical Economics, 20(2), 193\u2013199. https:\/\/doi.org\/10.1080\/13696998.2016.1241788","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"4183_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11136-015-1217-y","volume":"25","author":"MT King","year":"2016","unstructured":"King, M. T., Costa, D. S., Aaronson, N. K., Brazier, J. E., Cella, D. F., Fayers, P. M., Grimison, P., Janda, M., Kemmler, G., Norman, R., Pickard, A. S., Rowen, D., Velikova, G., Young, T. A., & Viney, R. (2016). QLU-C10D: A health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Quality of Life Research, 25(3), 625\u2013636. https:\/\/doi.org\/10.1007\/s11136-015-1217-y","journal-title":"Quality of Life Research"},{"issue":"1","key":"4183_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-02002-z","volume":"20","author":"H McTaggart-Cowan","year":"2022","unstructured":"McTaggart-Cowan, H., King, M. T., Norman, R., Costa, D. S. J., Pickard, A. S., Viney, R., & Peacock, S. J. (2022). The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): A Canadian valuation study. Health and Quality of Life Outcomes, 20(1), Article 97. https:\/\/doi.org\/10.1186\/s12955-022-02002-z","journal-title":"Health and Quality of Life Outcomes"},{"issue":"4","key":"4183_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10198-024-01730-x","volume":"26","author":"RH Xu","year":"2025","unstructured":"Xu, R. H., Zhao, Z., Pan, T., Monteiro, A., Gu, H., & Dong, D. (2025). Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin\u2019s lymphoma. European Journal of Health Economics, 26(4), 671\u2013682. https:\/\/doi.org\/10.1007\/s10198-024-01730-x","journal-title":"European Journal of Health Economics"},{"issue":"5","key":"4183_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33(5), 337\u2013343. https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Annals of Medicine"},{"issue":"4","key":"4183_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo, N., Liu, G., Li, M., Guan, H., Jin, X., & Rand-Hendriksen, K. (2017). Estimating an EQ-5D-5L value set for China. Value in Health, 20(4), 662\u2013669. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016","journal-title":"Value in Health"},{"issue":"6","key":"4183_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/mlr.0000000000001325","volume":"58","author":"JE Brazier","year":"2020","unstructured":"Brazier, J. E., Mulhern, B. J., Bjorner, J. B., Gandek, B., Rowen, D., Alonso, J., Vilagut, G., & Ware, J. E. (2020). Developing a new version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Medical Care, 58(6), 557\u2013565. https:\/\/doi.org\/10.1097\/mlr.0000000000001325","journal-title":"Medical Care"},{"issue":"5","key":"4183_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40273-020-00997-1","volume":"39","author":"J Wu","year":"2021","unstructured":"Wu, J., Xie, S., He, X., Chen, G., Bai, G., Feng, D., Hu, M., Jiang, J., Wang, X., Wu, H., Wu, Q., & Brazier, J. E. (2021). Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension. PharmacoEconomics, 39(5), 521\u2013535. https:\/\/doi.org\/10.1007\/s40273-020-00997-1","journal-title":"PharmacoEconomics"},{"issue":"3","key":"4183_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s11136-015-1115-3","volume":"25","author":"R Norman","year":"2016","unstructured":"Norman, R., Viney, R., Aaronson, N. K., Brazier, J. E., Cella, D., Costa, D. S., Fayers, P. M., Kemmler, G., Peacock, S., Pickard, A. S., Rowen, D., Street, D. J., Velikova, G., Young, T. A., & King, M. T. (2016). Using a discrete choice experiment to value the QLU-C10D: Feasibility and sensitivity to presentation format. Quality of Life Research, 25(3), 637\u2013649. https:\/\/doi.org\/10.1007\/s11136-015-1115-3","journal-title":"Quality of Life Research"},{"issue":"12","key":"4183_CR32","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1007\/s11136-024-03776-z","volume":"33","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Xu, J., Norman, R., King, M. T., Kemmler, G., Huang, W., & Luo, N. (2024). Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D. Quality of Life Research, 33(12), 3335\u20133349. https:\/\/doi.org\/10.1007\/s11136-024-03776-z","journal-title":"Quality of Life Research"},{"key":"4183_CR33","doi-asserted-by":"publisher","unstructured":"The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. (2025). Value Health, 28(8), 1302. https:\/\/doi.org\/10.1016\/j.jval.2024.06.001","DOI":"10.1016\/j.jval.2024.06.001"},{"key":"4183_CR34","unstructured":"Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.) Statistical power analysis for the behavioral sciences."},{"issue":"1","key":"4183_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen, J. (1992). A power primer. Psychological Bulletin, 112(1), 155\u2013159. https:\/\/doi.org\/10.1037\/0033-2909.112.1.155","journal-title":"Psychological Bulletin"},{"issue":"2","key":"4183_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40271-020-00466-z","volume":"14","author":"X Zeng","year":"2021","unstructured":"Zeng, X., Sui, M., Liu, B., Yang, H., Liu, R., Tan, R. L., Xu, J., Zheng, E., Yang, J., Liu, C., Huang, W., Yu, H., & Luo, N. (2021). Measurement properties of the EQ-5D-5L and EQ-5D-3L in six commonly diagnosed cancers. Patient, 14(2), 209\u2013222. https:\/\/doi.org\/10.1007\/s40271-020-00466-z","journal-title":"Patient"},{"issue":"1","key":"4183_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-025-02332-8","volume":"23","author":"Y Tao","year":"2025","unstructured":"Tao, Y., Cao, Y., Xu, L., Shi, J., Leng, L., Yang, H., Zhai, T., & Huang, W. (2025). Health utility scores of six common cancers in China measured by SF-6Dv2. Health and Quality of Life Outcomes, 23(1), Article 5. https:\/\/doi.org\/10.1186\/s12955-025-02332-8","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"4183_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/bm.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina, D. (2015). Understanding Bland Altman analysis. Biochemia Medica, 25(2), 141\u2013151. https:\/\/doi.org\/10.11613\/bm.2015.015","journal-title":"Biochemia Medica"},{"issue":"1","key":"4183_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s41669-023-00448-5","volume":"8","author":"MT King","year":"2024","unstructured":"King, M. T., Revicki, D. A., Norman, R., M\u00fcller, F., Viney, R. C., Pickard, A. S., Cella, D., & Shaw, J. W. (2024). United States value set for the functional assessment of cancer therapy-general eight dimensions (FACT-8D), a cancer-specific preference-based quality of life instrument. PharmacoEconomics - Open, 8(1), 49\u201363. https:\/\/doi.org\/10.1007\/s41669-023-00448-5","journal-title":"PharmacoEconomics - Open"},{"issue":"1","key":"4183_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., Bouter, L. M., & de Vet, H. C. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"4183_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-024-02297-0","volume":"22","author":"M Li","year":"2024","unstructured":"Li, M., Fang, B., Gu, H., & Jiang, Y. (2024). EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China. Health and Quality of Life Outcomes, 22(1), Article 80. https:\/\/doi.org\/10.1186\/s12955-024-02297-0","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"4183_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10552-023-01789-6","volume":"35","author":"NB Bulamu","year":"2024","unstructured":"Bulamu, N. B., Chen, G., McGrane, E., Cock, C., Young, G. P., & Symonds, E. L. (2024). Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: Improved discrimination with a cancer-specific scale. Cancer Causes & Control, 35(2), 347\u2013357. https:\/\/doi.org\/10.1007\/s10552-023-01789-6","journal-title":"Cancer Causes & Control"},{"key":"4183_CR43","doi-asserted-by":"publisher","unstructured":"Seyringer, S., & Gamper, E. M. (2025). Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients : Referring to: Pan, C. W., he, J. Y., Zhu, Y. B., Zhao, C. H., Luo, N., & Wang, P.: Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients. The European Journal of Health Economics, 24(6), 885\u2013893 (2003). Eur J Health Econ. https:\/\/doi.org\/10.1007\/s10198-025-01783-6","DOI":"10.1007\/s10198-025-01783-6"},{"issue":"3","key":"4183_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s41669-021-00265-8","volume":"5","author":"H Kim","year":"2021","unstructured":"Kim, H., Cook, G., Goodall, S., & Liew, D. (2021). Comparison of EQ-5D-3L with QLU-C10D in metastatic melanoma using cost-utility analysis. PharmacoEconomics - Open, 5(3), 459\u2013467. https:\/\/doi.org\/10.1007\/s41669-021-00265-8","journal-title":"PharmacoEconomics - Open"},{"issue":"1","key":"4183_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-024-00560-0","volume":"14","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Li, H., Cheng, L. J., King, M. T., Kemmler, G., Cella, D., Yu, H., Huang, W., & Luo, N. (2024). A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances. Health Economics Review, 14(1), Article 79. https:\/\/doi.org\/10.1186\/s13561-024-00560-0","journal-title":"Health Economics Review"},{"issue":"12","key":"4183_CR46","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s11136-024-03774-1","volume":"33","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Zhang, H., Luo, N., Li, H., Cheng, L. J., & Huang, W. (2024). Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients. Quality of Life Research, 33(12), 3309\u20133322. https:\/\/doi.org\/10.1007\/s11136-024-03774-1","journal-title":"Quality of Life Research"},{"key":"4183_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1657249","volume":"15","author":"J Sun","year":"2025","unstructured":"Sun, J., Xu, L., Cao, Y., Shi, J., Wang, Y., Wu, L., Yu, H., Liu, J., & Huang, W. (2025). Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China. Frontiers in Oncology, 15, Article 1657249. https:\/\/doi.org\/10.3389\/fonc.2025.1657249","journal-title":"Frontiers in Oncology"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04183-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:59:25Z","timestamp":1778680765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-026-04183-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4183"],"URL":"https:\/\/doi.org\/10.1007\/s11136-026-04183-2","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this cohort study received approval from the Ethics Committee of Harbin Medical University (HMUIRB2023005) and was conducted in accordance with the principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All individuals provided the informed consent in current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"93"}}